Oppenheimer & Co’s Surface Oncology, Inc. Common Stock SURF Stock Holding History

Oppenheimer & Co’s Portfolio SURF Stock Details SURF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-10,733	Closed	-$7.5K	–	1502
2023 Q1	$7.5K	Hold	10,733	–	–	﹤0.01%	1377
2022 Q4	$8.8K	Hold	10,733	–	–	﹤0.01%	1344
2022 Q3	$11K	Sell	10,733 -316	-3%	-$505	﹤0.01%	1355
2022 Q2	$18K	Hold	11,049	–	–	﹤0.01%	1391
2022 Q1	$32K	Hold	11,049	–	–	﹤0.01%	1451
2021 Q4	$53K	Sell	11,049 -21,348	-66%	-$138K	﹤0.01%	1464
2021 Q3	$245K	Sell	32,397 -2,437	-7%	-$15.6K	﹤0.01%	1308
2021 Q2	$260K	Buy	34,834 +4,870	+16%	+$37.5K	﹤0.01%	1312
2021 Q1	$234K	Buy	+29,964	New	+$300K	﹤0.01%	1282

Other funds holding SURF

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

AVAI

Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oppenheimer & Co's SURF Position: Q2 2023 in Review

Oppenheimer & Co sold out of Surface Oncology, Inc. Common Stock (SURF) in Q2 2023, closing a stake of 10,733 shares — an estimated $7.5K sold.

Oppenheimer & Co first reported a position in SURF in Q1 2021 and held it in 9 quarters. The position peaked at $260K in Q2 2021. 61 funds tracked by Wall St. Rank hold SURF as of Q2 2023.

Oppenheimer & Co reported no remaining Surface Oncology, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Oppenheimer & Co sold 10,733 Surface Oncology, Inc. Common Stock shares in Q2 2023, an estimated $7.5K.
Oppenheimer & Co first reported a position in Surface Oncology, Inc. Common Stock in Q1 2021 and held it in 9 quarters.
Oppenheimer & Co's Surface Oncology, Inc. Common Stock position peaked at $260K in Q2 2021.
61 funds tracked by Wall St. Rank held Surface Oncology, Inc. Common Stock as of Q2 2023.

Based on Oppenheimer & Co's 13F filing for Q2 2023, filed 3 Aug 2023.